Entropy Technologies LP Trims Holdings in Cencora, Inc. (NYSE:COR)

Entropy Technologies LP lessened its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 62.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,194 shares of the company's stock after selling 15,354 shares during the quarter. Entropy Technologies LP's holdings in Cencora were worth $2,069,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD bought a new stake in shares of Cencora in the 1st quarter valued at approximately $2,183,619,000. JPMorgan Chase & Co. bought a new position in Cencora during the first quarter valued at $1,199,695,000. Boston Partners purchased a new stake in shares of Cencora in the first quarter valued at $1,001,269,000. Capital Research Global Investors bought a new stake in shares of Cencora in the 1st quarter worth about $650,424,000. Finally, Bessemer Group Inc. bought a new position in Cencora during the 1st quarter valued at about $556,245,000. Institutional investors own 97.52% of the company's stock.

Insider Activity

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 15.80% of the company's stock.

Cencora Stock Up 0.6 %

Shares of COR traded up $1.38 during mid-day trading on Wednesday, hitting $250.17. The company's stock had a trading volume of 552,548 shares, compared to its average volume of 1,404,619. The company's 50-day moving average is $232.24 and its 200-day moving average is $230.86. Cencora, Inc. has a 52-week low of $191.11 and a 52-week high of $251.56. The firm has a market capitalization of $49.30 billion, a price-to-earnings ratio of 33.35, a PEG ratio of 1.66 and a beta of 0.44. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be issued a $0.55 dividend. The ex-dividend date is Friday, November 15th. This is an increase from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.88%. Cencora's dividend payout ratio (DPR) is currently 27.16%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on COR shares. Evercore ISI boosted their target price on Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. StockNews.com downgraded Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Barclays boosted their target price on shares of Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. UBS Group upped their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, Leerink Partners decreased their price objective on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a report on Monday, October 7th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and a consensus price target of $271.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.